APLS — Apellis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $6.24bn
- $6.30bn
- $396.59m
Annual cashflow statement for Apellis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -305 | -345 | -746 | -652 | -529 |
| Depreciation | |||||
| Non-Cash Items | 40.2 | 164 | 275 | 153 | 132 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 53.1 | 19.6 | -93.5 | -15.7 | -200 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -211 | -160 | -563 | -514 | -595 |
| Capital Expenditures | -1.69 | -5.42 | -1.1 | -1.52 | -0.773 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -312 | 249 | 61.4 | 0.099 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.69 | -317 | 248 | 59.9 | -0.674 |
| Financing Cash Flow Items | 91.6 | -23.1 | -5.79 | -5.68 | -11 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 389 | 692 | 392 | 366 | 394 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 176 | 215 | 74.7 | -88.7 | -201 |